Company Overview

Conavi Medical Corp. is a medical technology company focused on the development and commercialization of intravascular imaging systems used to support the diagnosis and treatment of coronary artery disease. The company operates within the medical devices and cardiovascular imaging industries, with products designed for use by interventional cardiologists in catheterization laboratories. Its core value proposition is the integration of multiple imaging modalities into a single platform to provide enhanced visualization of coronary arteries.

The company’s primary revenue drivers are its intravascular imaging platforms, most notably Novasight Hybrid™ IVUS-OCT System and Novasight™ 3D IVUS System, which combine structural and compositional vessel imaging. Conavi Medical targets hospitals and cardiac care centers, primarily in developed healthcare markets. Founded in Canada, the company evolved from early-stage imaging research into a commercial-stage medical device company through regulatory approvals, clinical validation, and strategic partnerships aimed at expanding adoption of hybrid intravascular imaging.

Business Operations

Conavi Medical’s operations center on the design, manufacture, and commercialization of catheter-based imaging systems and related disposable components. The company generates revenue through the sale of capital equipment systems and recurring revenue from single-use imaging catheters. Its business is organized around its imaging technology platforms rather than distinct reporting segments, with Novasight Hybrid™ IVUS-OCT representing its flagship offering.

Operations are primarily based in Canada and the United States, with clinical and commercial activities extending into select international markets through distributors and research collaborations. The company controls proprietary optical and ultrasound imaging technologies and related intellectual property. Public disclosures indicate no large-scale manufacturing subsidiaries; production and distribution activities are supported through a combination of in-house capabilities and third-party suppliers. Data on joint ventures or material equity partnerships is inconclusive based on available public sources.

Strategic Position & Investments

Conavi Medical’s strategic direction emphasizes the adoption of hybrid and advanced intravascular imaging to improve procedural decision-making in interventional cardiology. Growth initiatives have focused on regulatory approvals, physician training, and expanding clinical evidence supporting the use of combined IVUS and OCT imaging. The company has highlighted continued investment in next-generation imaging capabilities and workflow integration as part of its long-term strategy.

The company has not disclosed material acquisitions of other operating businesses in recent public filings. Strategic investment activity has primarily taken the form of internal research and development rather than external M&A. Conavi Medical’s technology portfolio positions it within the emerging segment of high-resolution, multi-modality cardiovascular imaging, which management has identified as a differentiator versus single-modality competitors.

Geographic Footprint

Conavi Medical is headquartered in Toronto, Canada, which serves as its primary center for corporate management, research, and development. The company maintains a commercial presence in North America, with the United States representing a key target market due to its large interventional cardiology base and reimbursement environment.

Internationally, Conavi Medical has pursued market entry through regulatory approvals, distributor relationships, and clinical evaluations in parts of Europe and other select regions. While global in ambition, its operational footprint remains concentrated in developed healthcare markets, and the scale of international revenues has not been consistently disclosed in public sources.

Leadership & Governance

Conavi Medical is led by an executive team with experience in medical devices and healthcare technology. The company was founded by individuals with technical and clinical expertise in intravascular imaging; however, detailed founder attribution varies across public disclosures, and data is inconclusive based on available public sources. Governance follows a typical public-company structure with a board of directors overseeing strategy and management performance.

Key executives identified in public company materials include:

• Thomas Looby – Chief Executive Officer
• Multiple additional senior executives – Data inconclusive based on available public sources

The leadership team has articulated a strategic vision centered on clinical differentiation through technology innovation, disciplined capital deployment, and expanding physician adoption of advanced imaging tools.